Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
30.10.2023 - Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will report ...
United States Pulse Biosciences Inc About Pulse Pulsed Field Ablation Nano Pulse Stimulation Pulse Biosciences
Source: wallstreet-online.de